Belite Bio vs Ligand Pharmaceuticals

Belite Bio (BLTE), health care, and Ligand Pharmaceuticals (LGND), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Belite Bio is worth $6.4B on the stock market and Ligand Pharmaceuticals $5.9B: Belite Bio is valued at 8% more. Over the past year Belite Bio's share price has moved +32.0% and Ligand Pharmaceuticals's +45.7%.

Key facts

Belite Bio market value
$6.4B
Ligand Pharmaceuticals market value
$5.9B
Ligand Pharmaceuticals P/E
118
Ligand Pharmaceuticals revenue
$268.1MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Belite Bio vs Ligand Pharmaceuticals: every measure side by side
Measure Belite Bio Ligand Pharmaceuticals
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$6.4Bhigher$5.9Blower
Revenue—$268.1M
Earnings-$77.6Mlower$124.5Mhigher
Employees41lower47higher
Total assets$780.6Mlower$1.6Bhigher
Valuation
P/E—118
P/S—21.9
P/B8.1higher6.1lower
Dividend yield0.00%0.00%
Profitability
Operating margin—15.3%
Balance sheet
Net assets$770.5Mlower$1Bhigher
Total liabilities$10.1Mlower$543.4Mhigher
Total debt——
Cash on hand$352.9Mhigher$174.9Mlower
Price change
Today-2.98%lower-2.62%higher
1 year+32.0%lower+45.7%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Belite Bio only (2)

Ligand Pharmaceuticals only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns BLTE

Further comparisons

Learn

Questions and answers

Which is bigger, Belite Bio or Ligand Pharmaceuticals?

By market value, Belite Bio is the larger: $6.4B against $5.9B for Ligand Pharmaceuticals.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Belite Bio and Ligand Pharmaceuticals?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Belite Bio and 0 hold Ligand Pharmaceuticals.

Cite this page

Funkfolio, “Belite Bio vs Ligand Pharmaceuticals”, data as of 18 November 2026. https://funkfolio.com/compare/blte-vs-lgnd

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.